CHARACTERISTICS OF WOMEN WITH A FAMILY HISTORY OF OVARIAN-CANCER .2. FOLLICULAR PHASE HORMONE LEVELS

被引:0
|
作者
CRAMER, DW [1 ]
BARBIERI, RL [1 ]
MUTO, MG [1 ]
KELLY, A [1 ]
BRUCKS, JP [1 ]
HARLOW, BL [1 ]
机构
[1] BRIGHAM & WOMENS HOSP, DEPT OBSTET & GYNECOL, BOSTON, MA 02115 USA
关键词
OVARIAN CANCER; GONADOTROPINS; CA; 125; FAMILIAL; ESTRADIOL; GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE;
D O I
10.1002/1097-0142(19940815)74:4<1318::AID-CNCR2820740422>3.0.CO;2-V
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Although there is a basis for linking pituitary or ovarian hormones with experimentally induced ovarian cancer, establishing their role in women is complicated because the usual case-control methods cannot be applied. In this study, hormonal levels in women with a family history of ovarian cancer (FOC) and who are at higher risk for the disease are compared with women without such a history. Methods. The authors studied 106 unrelated women (FOC patients) with at least one primary or two second-degree relatives with ovarian cancer compared with 116 age- and residence-matched controls without a family history of ovarian cancer (FOC control subjects). All women were premenopausal, between the ages of 25 and 49 years, not currently using oral contraceptives, and had blood drawn during the early follicular phase for gonadotropins, estradiol (E(2)), and CA-125. Results. Women with a family history of ovarian cancer and control subjects did not differ significantly in follicle stimulating hormone (FSH) levels, E(2), or CA-125. Patients with a family history of ovarian cancer had significantly lower luteinizing hormone (LH) levels compared with control subjects and produced more E(2) and FSH relative to their level of LH. The ratios of LH to E(2) and LH to FSH were correlated with the enzymatic activity of galactose-1-phosphate uridyl transferase, which was shown previously to differ between FOC patients and control subjects. Conclusion. Lower LH and higher E(2) are reported in women with breast, endometrial, and ovarian cancer (before surgery). The authors speculate that these observations reflect greater LH binding and estradiol production in ovaries at risk for these cancers-the ovarian cortical hyperplasia postulated in older gynecologic literature as the precursor to estrogen dependent neoplasia.
引用
收藏
页码:1318 / 1322
页数:5
相关论文
共 46 条
  • [31] ASSOCIATION BETWEEN PRETREATMENT CA-125 LEVELS AND SURGICALLY DOCUMENTED COMPLETE RESPONSES IN PATIENTS WITH OVARIAN-CANCER TREATED WITH 2ND-LINE INTRAPERITONEAL THERAPY
    MARKMAN, M
    REICHMAN, B
    HAKES, T
    CURTIN, J
    BARAKAT, R
    RUBIN, S
    JONES, W
    LEWIS, JL
    ALMADRONES, L
    HOSKINS, W
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 118 (05) : 391 - 394
  • [32] Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
    Egloff, Heidi
    Jatoi, Aminah
    CANCER INVESTIGATION, 2016, 34 (10) : 531 - 535
  • [33] PHASE-II STUDY OF INTRAPERITONEAL CISPLATIN PLUS SYSTEMIC ETOPOSIDE AS 2ND-LINE TREATMENT IN PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER
    DEJONG, RS
    WILLEMSE, PHB
    BOONSTRA, H
    DEVRIES, EGE
    VANDERGRAAF, WTA
    SLEIJFER, DT
    VANDERZEE, AGJ
    MULDER, NH
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) : 709 - 713
  • [34] Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels
    Coticchia, Christine M.
    Curatolo, Adam S.
    Zurakowski, David
    Yang, Jiang
    Daniels, Kathryn E.
    Matulonis, Ursula A.
    Moses, Marsha A.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 295 - 300
  • [35] Novel loss-of-function mutation in BRCA2 gene identified in a Chinese female with a family history of ovarian cancer: A case report
    Cui, Yanzhi
    Wang, Yanyan
    Zhang, Ningzhi
    He, Jun
    Huang, Hui
    Liu, Fengling
    Wei, Suju
    Dong, Qian
    Wu, Jing
    Lin, Keke
    Chen, Weixi
    Xiang, Jiale
    Jin, Hui
    Peng, Zhiyu
    Zhao, Qiang
    Li, Wei
    Jiang, Da
    Banerjee, Santasree
    ONCOLOGY LETTERS, 2019, 17 (03) : 3350 - 3354
  • [36] Family History and BRCA1/BRCA2 Status Among Japanese Ovarian Cancer Patients and Occult Cancer in a BRCA1 Mutant Case
    Hirasawa, Akira
    Masuda, Kenta
    Akahane, Tomoko
    Ueki, Arisa
    Yokota, Megumi
    Tsuruta, Tomohiko
    Nomura, Hiroyuki
    Kataoka, Fumio
    Tominaga, Eiichiro
    Banno, Kouji
    Makita, Kazuya
    Susumu, Nobuyuki
    Sugano, Kokichi
    Kosaki, Kenjiro
    Kameyama, Kaori
    Aoki, Daisuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (01) : 49 - 56
  • [37] SERUM HORMONE LEVELS IN PREMENOPAUSAL CHINESE WOMEN IN SHANGHAI AND WHITE WOMEN IN LOS-ANGELES - RESULTS FROM 2 BREAST-CANCER CASE-CONTROL STUDIES
    BERNSTEIN, L
    YUAN, JM
    ROSS, RK
    PIKE, MC
    HANISCH, R
    LOBO, R
    STANCZYK, F
    GAO, YT
    HENDERSON, BE
    CANCER CAUSES & CONTROL, 1990, 1 (01) : 51 - 58
  • [38] Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer Results of a Phase 2 Study
    McGonigle, Kathryn F.
    Muntz, Howard G.
    Vuky, Jacqueline
    Paley, Pamela J.
    Veljovich, Dan S.
    Greer, Benjamin E.
    Goff, Barbara A.
    Gray, Heidi J.
    Malpass, Thomas W.
    CANCER, 2011, 117 (16) : 3731 - 3740
  • [39] Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
    Engel, Christoph
    Rhiem, Kerstin
    Hahnen, Eric
    Loibl, Sibylle
    Weber, Karsten E.
    Seiler, Sabine
    Zachariae, Silke
    Hauke, Jan
    Wappenschmidt, Barbara
    Waha, Anke
    Bluemcke, Britta
    Kiechle, Marion
    Meindl, Alfons
    Niederacher, Dieter
    Bartram, Claus R.
    Speiser, Dorothee
    Schlegelberger, Brigitte
    Arnold, Norbert
    Wieacker, Peter
    Leinert, Elena
    Gehrig, Andrea
    Briest, Susanne
    Kast, Karin
    Riess, Olaf
    Emons, Guenter
    Weber, Bernhard H. F.
    Engel, Jutta
    Schmutzler, Rita K.
    BMC CANCER, 2018, 18
  • [40] BIWEEKLY 2-DAY SCHEDULE OF HIGH-DOSE FOLINIC ACID, 5-FLUOROURACIL BOLUS AND INFUSION IN PRETREATED ADVANCED EPITHELIAL OVARIAN-CANCER - A PHASE-II STUDY
    LOUVET, C
    DEGRAMONT, A
    DEMUYNCK, B
    VARETTE, C
    BEERBLOCK, K
    BENNAMOUN, M
    KRULIK, M
    ANNALS OF ONCOLOGY, 1992, 3 (08) : 657 - 658